

Jardiance®  
(empagliflozin)

JARDIANCE-NOW also APPROVED for HFpEF

# IMPACT HEART FAILURE LIKE NEVER BEFORE

With JARDIANCE

The 1<sup>st</sup> medicine clinically proven\* and approved\* to reduce the risk of CV death or HHF across the LVEF spectrum<sup>††-‡</sup>



References: 1. Sirtanov\* Analysis providing information. 2. Felker B, Butler J, et al. EMPEROR-Reduced Mortality, Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*. 2023;389(10):1049-1059. [EMPEROR-Reduced mortality and the publisher's Supplementary Appendix]. 3. Anker SD, Butler J, Filippatos G, et al. DAPA-HF Preserved-LVEF Investigators. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*. 2021;384(12):1219-1230. [DAPA-HF Preserved results and the publisher's Supplementary Appendix].

**Indication**

Adult patients with chronic heart failure (NYHA class I, II, or IV) and reduced ejection fraction (LVEF < 40%). Adult patients with chronic heart failure (NYHA class I, II, or IV) and preserved ejection fraction (LVEF > 40%).<sup>††</sup> Treatment with the primary endpoint in clinical trials and being published in peer-reviewed journals. \* Jardiance 10mg is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class I-IV)†† (CV=cardiovascular; HFpEF=heart failure with preserved ejection fraction; non-steroidal anti-inflammatory drugs; ACE=angiotensin-converting enzyme; SGLT2= sodium-glucocorticoid cotransporter 2). †† Jardiance is the first and only medicine clinically proven and approved to reduce the risk of CV death or HHF across the LVEF spectrum in Malaysia.

For healthcare professionals only



Boehringer  
Ingelheim

Boehringer Ingelheim (Malaysia) Sdn. Bhd.  
Dagangrajah No. 108/2000452 (146102.0)  
Suite 10-G Level 10, Wisma UIC, Damansara E,  
No. 6, Jalan Chungkang Sarawakan, Damansara Heights,  
60460 Kuala Lumpur.  
Tel: +603 2092 0088 Fax: +603 2095 2876



SCAN QR CODE TO ACCESS  
JARDIANCE® label  
prescribing information

PC-MY-102809 JAN 2023